免疫检查点抑制剂在肺癌中的应用:影像学考量
本文综述免疫检查点抑制剂治疗非小细胞肺癌的作用机制,重点介绍常见不良事件的影像表现,并讨论用于评估独特治疗反应模式的新影像学标准。靶向PD-1/PD-L1轴的单克隆抗体在3期临床试验中头对头比较显示总生存优于传统细胞毒性化疗,纳武利尤单抗、帕博利珠单抗和阿替利珠单抗已获美国FDA批准用于晚期NSCLC。
要点
- 免疫检查点抑制剂治疗反应模式和不良事件影像表现均不同于传统化疗。
- 靶向PD-1/PD-L1轴的抗体在3期试验中头对头比较显示总生存优于传统化疗。
- 放射科医生需熟悉这类药物及其独特影像表现以准确评估疗效和毒性。
核心结论
- 免疫检查点抑制剂是癌症治疗的突破,在多种恶性肿瘤中显示前所未有的成功;靶向PD-1/PD-L1轴的单克隆抗体在NSCLC 3期试验头对头比较中总生存优于传统细胞毒性化疗,纳武利尤单抗、帕博利珠单抗和阿替利珠单抗已获美国FDA批准用于晚期NSCLC。
研究设计与样本
- 综述,回顾免疫检查点抑制剂在非小细胞肺癌治疗中的作用机制、常见不良事件影像表现及评估独特治疗反应模式的新影像学标准。
临床应用与阅片要点
- 放射科医生应熟悉免疫检查点抑制剂及其独特影像表现,以识别治疗相关不良事件并应用新标准评估独特治疗反应模式。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The purpose of this article is to review the mechanisms of action of immune checkpoint inhibitors in the treatment of non-small cell lung cancer (NSCLC), highlight imaging manifestations of common adverse events, and discuss new criteria for using imaging to assess unique treatment response patterns.
CONCLUSION: Immune checkpoint inhibitor therapy is a breakthrough in cancer treatment that has shown unprecedented success when used for a variety of malignancies. In recent phase 3 clinical trials for NSCLC, monoclonal antibodies that target the programmed death-1 (PD-1) receptor and its ligand PD-L1 (i.e., the PD-1/PD-L1 axis) were associated with better overall survival in head-to-head comparisons with conventional cytotoxic chemotherapy. On the strength of the results of these trials, the PD-1 inhibitors nivolumab and pembrolizumab and the PD-L1 inhibitor atezolizumab recently received regulatory approval by the U.S. Food and Drug Administration for the treatment of advanced NSCLC. Because of their unique mechanisms of action, these agents differ from conventional cytotoxic chemotherapy in both patterns of treatment response and treatment-related adverse events. Given the rapidly expanding clinical use of immune checkpoint inhibitors and the central role of radiology in the care of patients with lung cancer, it is important for radiologists to be familiar with these agents and their unique imaging findings.
引用
- Wang GX, Guo LQ, Gainor JF, et al. Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations. AJR Am J Roentgenol. 2017. PMID: 28657846. doi:10.2214/AJR.16.17770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。